Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function. - Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042481

Enrollment

Registered

2020-11-18

Start date

2020-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

Semaglutide group: In hospitalization, participants receive semaglutide 0.25mg once a week. After discharge, participants receive semaglutide 0.50mg once a week in 12 weeks. After 12 weeks of disch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) type2 diabetic inpatients 2) Patients who are over 20 years or older 3) Patinets never using GLP-1 receptor agonists 4) Diabetes duration within 10 years 5) Patients with the written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with severe liver dysfunction 2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 4) Patinet with diabetic ketoacidosis 5) Patient with infection 6) Patients taking steroid 7) Patients with malignant tumor currently undergoing treatment 8) Pregnant or lactating woman 9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor

Design outcomes

Primary

Measure	Time frame
HbA1c levels in one year after discharge.	—

Countries

Japan

Contacts

Public ContactTaichi Minami

Saiseikai Yokohamashi Nanbu Hospital Department of Diabetes and Endocrinology

ksqdd034@yahoo.co.jp045-832-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026